Internal Medicine, Hematology & Oncology · Orland Park, IL
NPI
1801243738
Since 2016
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
15300 West Ave Ste 108
Orland Park, IL, 60462
Phone (708) 226-2318
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.3M
155,691 services
Medicare patients, 2024
636
Average age 74
Drug cost, 2024
$3.0M
1,892 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Yazan Numan was code J9271 (injection, pembrolizumab, 1 mg), 19,000 times for 28 patients. In total Yazan Numan billed 155,691 services in 139 codes, and Medicare paid $3.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-09-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,000 | 28 | $44.78 | $851K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 17,250 | 48 | $0.11 | $1,915 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 15,202 | 12 | $0.06 | $872 |
| J9075 Injection, cyclophosphamide, not otherwise specified, 5 mg | Office | 5,700 | 11 | $0.77 | $4,366 |
| J0897 Injection, denosumab, 1 mg | Office | 4,980 | 14 | $20.78 | $103K |
| J9267 Injection, paclitaxel, 1 mg | Office | 4,823 | 12 | $0.08 | $386 |
| J9305 Injection, pemetrexed, not otherwise specified, 10 mg | Office | 3,290 | 11 | $3.55 | $12K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,668 | 83 | $0.09 | $240 |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2,640 | 19 | $16.11 | $43K |
| Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 2,640 | 13 | $15.84 | $42K |
| J0461 Injection, atropine sulfate, 0.01 mg | Office | 2,320 | 14 | $0.07 | $163 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,210 | 76 | $0.73 | $1,618 |
| 36415 Venipuncture Blood Collection | Office | 1,682 | 389 | $8.63 | $15K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 1,251 | 21 | $3.52 | $4,404 |
| 99215 Office E&M - Established | Office | 1,094 | 239 | $148.30 | $162K |
By year: 2022 $216K for 14,804 services; 2023 $1.8M for 80,728 services; 2024 $3.3M for 155,691 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,682 | 389 | $8.63 | $15K |
Medicare prescription drug claims, 2024
In 2024, the drug Yazan Numan prescribed most often to Medicare patients was Prednisone, with 154 prescriptions and refills. In total Yazan Numan wrote 1,892 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 154 | 155 | 64 | $514 |
| Acyclovir Generic | 139 | 168 | 37 | $1,995 |
| Eliquis Apixaban | 135 | 181 | 36 | $103K |
| Prochlorperazine Maleate Generic | 117 | 117 | 71 | $1,051 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 68 | 68 | 24 | $2,207 |
| Ondansetron Odt Ondansetron | 61 | 61 | 49 | $677 |
| Hydroxyurea Generic | 57 | 74 | 13 | $921 |
| Tramadol Hcl Generic | 46 | 46 | 26 | $156 |
| Dexamethasone Generic | 44 | 51 | 21 | $1,030 |
| Gabapentin Generic | 42 | 42 | 11 | $462 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 41 | 53 | 11 | $133 |
| Potassium Chloride Generic | 38 | 41 | 24 | $294 |
| Xtandi Enzalutamide | 38 | 38 | Under 11 | $536K |
| Levofloxacin Generic | 36 | 43 | 15 | $346 |
| Furosemide Generic | 35 | 47 | 17 | $96.74 |
Brand drugs: - claims; generic drugs: 1,481 claims; opioid claims: 194.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Yazan Numan were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.